fda semaglutide shortage resolved 2025 announcement declares february Novo's Wegovy and Ozempic removed from US list, compounders on notice FDA free to pursue semaglutide – GLP-1 Drugs: FDA Removes Semaglutide

Which FEHB Plans Offer Part D plans The following 20 FEHB plans will offer PDPs to their Medicare enrollees next year: Aetna Direct Consumer Option Aetna Open Access High, Basic (Mid-Atlantic) APWU High BCBS Basic, FEP Blue Focus, Standard Compass Rose High Foreign Service GEHA High, Standard (both new for 2025) HealthPartners High, Standard MHBP Consumer Option, Standard, Value NALC CDHP (new for 2025) , High SAMBA High, Standard Annuitants in these plans who have either Medicare Part A or Parts A and B will be automatically enrolled in the PDP (note: BCBS only auto-enrolls members who have both Parts A and B)

Effient (prasugrel) Effient is often prescribed for individuals who have undergone percutaneous coronary intervention, a procedure that aids in the opening of obstructed coronary (heart) arteries

RELATED: Phentermine alternatives | Adderall alternatives Warnings of phentermine and Adderall Phentermine may cause high blood pressure in the lungs (pulmonary hypertension)

- Emerging biosimilars like Omalizumab, Natalizumab, and Tocilizumab are gaining first approvals in both regions

Wegovy, the injectable version of semaglutide, is FDA-approved specifically for weight loss in people without diabetes